WO2014019468A1 - 哌嗪并三唑类化合物及其制备方法和制药用途 - Google Patents
哌嗪并三唑类化合物及其制备方法和制药用途 Download PDFInfo
- Publication number
- WO2014019468A1 WO2014019468A1 PCT/CN2013/079998 CN2013079998W WO2014019468A1 WO 2014019468 A1 WO2014019468 A1 WO 2014019468A1 CN 2013079998 W CN2013079998 W CN 2013079998W WO 2014019468 A1 WO2014019468 A1 WO 2014019468A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- group
- hydrogen
- unsubstituted
- fluorenyl
- Prior art date
Links
- DHNMGONLWNLUMV-UHFFFAOYSA-N CC(C)(C1)[n]2c(C(F)(F)F)nnc2CN1C(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)=O Chemical compound CC(C)(C1)[n]2c(C(F)(F)F)nnc2CN1C(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)=O DHNMGONLWNLUMV-UHFFFAOYSA-N 0.000 description 1
- QIWPQNRZCNMWQG-UHFFFAOYSA-N CC1(C)[n]2c(C(F)(F)F)nnc2CNC1 Chemical compound CC1(C)[n]2c(C(F)(F)F)nnc2CNC1 QIWPQNRZCNMWQG-UHFFFAOYSA-N 0.000 description 1
- PAXLJNGPFJEKQX-UHFFFAOYSA-N OC(c(cc(CC(c1ccccc11)=NNC1=O)cc1)c1F)=O Chemical compound OC(c(cc(CC(c1ccccc11)=NNC1=O)cc1)c1F)=O PAXLJNGPFJEKQX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the field of pharmacy, and in particular to a class of piperazine-triazole compounds having one or more substituents or isomers thereof, or a pharmaceutically acceptable salt, ester, prodrug or hydrate thereof,
- PARP1 novel highly selective poly ADP-ribose polymerase-1
- PARP Poly ADP-ribose polymerase-1
- PARP1 was the first cell ribozyme that catalyzed the function of poly ADP-ribosyl group.
- PARP2, PARP3, PARP4 (VPARP), PARP5a (tankyrase 1), PARP5b (tankyrase 2), PARP7 (TiPARP) were successively isolated. ) and subtypes such as sPARPl.
- sPARPl 18 structural subtypes with potential PARP activity have been identified based on the structure of the catalytic domain of PARP1.
- the structure of PARP1 is relatively complete, including three major domains: the N-terminal DNA binding domain (DBD), and the self-modifying domain ( AMD) and the catalytic domain at the C-terminus.
- DBD contains two zinc finger structures and a DNA strand break sensitive element (NLS), which receives signals from DNA strand breaks through NLS, and the zinc finger structure binds to the damaged DNA site and repairs it.
- NLS DNA strand break sensitive element
- PARP-2 has the highest degree of homology with PARP1 and has 69% homology. Therefore, the currently reported PARP1 inhibitors are quite active against PARP2.
- PARP1 predominates, including: 1) repairing DNA and maintaining genomic stability; 2) regulating transcription levels, regulating expression of related proteins; 3) affecting replication and differentiation, participating in maintenance Grain length; 4) Regulate cell death and remove damaged cells inside the body. Therefore, by inhibiting the activity of PARP1, PARP1-mediated DNA repair mechanism can be inhibited, and DNA damage of tumor cells can be improved by radiotherapy and chemotherapy, thereby treating tumors.
- PARP has a DNA repair function
- DNA damage is too difficult to be repaired, PARP is overactivated, tending to a "suicide mechanism" and consuming a large amount of substrate nicotinamide adenine dinucleotide (NAD + ) and ATP.
- NAD + substrate nicotinamide adenine dinucleotide
- ATP nicotinamide adenine dinucleotide
- the acceptor domain binds to the ADP site of the poly ADP-ribose chain.
- the supply domain is combined with NAD+, which can be divided into three sub-binding domains, namely the nicotinamide-ribose binding site (NI site), the phosphate binding site (PH site), and the adenosine-ribose binding site (AD site).
- PARP inhibitors interact with the NI site of PARP, competitively inhibiting NAD+, and thus have similarities to the structure of nicotinamide, such as AZD2281 (olaparib/KU-59436;) developed by AstraZeneca Pharmaceuticals.
- An oral PARP small molecule inhibitor that shows good development in the study of ovarian cancer, breast cancer and solid tumors in combination with drugs such as cisplatin, carboplatin and paclitaxel
- compound AZD2281 has a shorter duration of action and half-life ( ⁇ 1 hour) and lower bioavailability ( ⁇ 15%), which makes further development difficult.
- cyclic tertiary amines in the molecular structure are one of the main causes of metabolic instability.
- the cyclic tertiary amine forms the oxidation product I or the imine intermediate II (as shown in the figure above) by the action of an oxidase or a P450 metabolic enzyme, thereby producing a series of oxidation products including N-demethylation and cyclohydroxylation.
- Metabolites such as a-carbonylation, N-oxidation, and ring-opening, resulting in inactivation of drug molecules, and even toxicity, such as partial cyclic tertiary amines, metabolized by imine intermediates to MPTP (1-methyl-4) -Phenyl-1, 2,3,6-tetrahydropyridine;) or phencyclidine ( hallucinogen), etc. to produce central nervous system toxicity.
- AZD2281 is less selective for members of the PARP family, especially for the telomerases Tankyrasel and Tankyrase 2, which may lead to safety risks.
- the present invention mainly analyzes the crystal structure of PARP1 and its binding characteristics to small molecule compounds such as AZD2281, and retains the key hydrogen bonding site, ie, the amide fragment, which affects the activity, and focuses on structural modification of its hydrophobic action region.
- Another object of the invention is to provide a process for the preparation of such compounds.
- a further object of the present invention is to provide the use of such a compound as a novel highly selective PARP1 inhibitor for the preparation of a medicament for the prevention and/or treatment of a disease associated with PARP (poly ADP-ribose polymerase), said with PARP Related diseases include various ischemic diseases (brain, umbilical cord, heart, digestive tract, retina, etc.), neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, muscular dystrophy, etc.) and cancer (breast cancer) , ovarian cancer, liver cancer, melanoma, prostate cancer, colon cancer, gastric cancer and solid tumors, etc.).
- Another object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of one or more piperazine-triazole compounds or a pharmaceutically acceptable salt, ester, prodrug or hydrate thereof.
- the present invention provides a piperazine triazole compound represented by the following formula I or an isomer thereof or a pharmaceutically acceptable salt, ester, prodrug or hydrate thereof:
- a and B are each independently hydrogen or a substituted or unsubstituted C1-C8 hydrocarbon group, and A and B are not simultaneously hydrogen, wherein the substituted substituent is selected from the group consisting of halogen, cyano, nitro, hydroxy and Amino group;
- a and B together with the attached carbon atom form a substituted or unsubstituted C4-C8 aliphatic ring, a substituted or unsubstituted C6-C10 aromatic ring, substituted or unsubstituted containing 1-3 selected from N, a 4-8 membered heterocyclic ring of 0 and S atoms, or a substituted or unsubstituted 5-8 membered aromatic heterocyclic ring containing 1-3 selected from N, 0 and S atoms, wherein the substituted substituent is selected from the group consisting of Halogen, cyano, nitro, hydroxy and amino;
- X is hydrogen, halogen, hydroxy or cyano
- Y is hydrogen or a substituted or unsubstituted C1-C8 alkyl group, and the substituted substituent is selected from the group consisting of 3 ⁇ 4, cyano, nitro, hydroxy, amino, C1-C6 decyloxy, C2-C6 fluorene carbonyl, C2 -C6 oxime carbonyl, C2-C6 alkenyl, C2-C6 alkynyl and C6-C10 aryl;
- G is hydrogen, C1-C6 fluorenyl, C1-C6 decyloxy, C2-C6 fluorenylcarbonyl, C1-C6 decylamino or (C1-C6 fluorenyl) 2 amino;
- Z is hydrogen, C1-C6 fluorenyl, C1-C6 decyloxy, C2-C6 fluorene carbonyl, C1-C6 decylamino or (C1-C6 fluorenyl) 2 amino;
- R is selected from hydrogen or a substituted or unsubstituted C1-C8 fluorenyl group; the substituted substituent is selected from the group consisting of halogen, cyano, nitro, hydroxy, amino, C1-C6 decyloxy, C2-C6 fluorene carbonyl, C2 -C6 oxime carbonyl and C6-C10 aryl.
- Each of ruthenium and osmium is independently hydrogen, a substituted or unsubstituted C1-C8 fluorenyl group, a substituted or unsubstituted C2-C8 alkenyl group, or a substituted or unsubstituted C2-C8 alkynyl group, and A and B are not simultaneously Is hydrogen, wherein the substituted substituent is selected from the group consisting of halogen, cyano, nitro, hydroxy and amino;
- a and B together with the attached carbon atom form a substituted or unsubstituted C4-C7 aliphatic ring, a substituted or unsubstituted C6-C8 aromatic ring, substituted or unsubstituted containing 1-3 selected from N, a 4-7 membered heterocyclic ring of 0 and S atoms, or a substituted or unsubstituted 5-7 membered aromatic heterocyclic ring containing 1-3 selected from N, 0 and S atoms, wherein the substituted substituent is selected from the group consisting of Halogen, cyano, nitro, hydroxy and amino;
- X is hydrogen, halogen, hydroxy or cyano
- Y is hydrogen or a substituted or unsubstituted C1-C6 alkyl group, and the substituted substituent is selected from the group consisting of 3 ⁇ 4, cyano, nitro, Hydroxy, amino, C1-C4 decyloxy, C2-C4 fluorenylcarbonyl, C2-C4 fluorenyloxycarbonyl, C2-C4 alkenyl, C2-C4 alkynyl and C6-C8 aryl;
- G is hydrogen, C1-C4 fluorenyl, C1-C4 decyloxy, C2-C4 fluorenylcarbonyl, C1-C4 decylamino or (C1-C4 fluorenyl) 2 amino;
- Z is hydrogen, C1-C4 fluorenyl, C1-C4 decyloxy, C2-C4 fluorenylcarbonyl, C1-C4 decylamino or (C1-C4 fluorenyl) 2 amino;
- R is selected from hydrogen, substituted or unsubstituted C1-C6 fluorenyl; the substituted substituent is selected from the group consisting of a cyano group, a cyano group, a nitro group, a hydroxyl group, an amino group, a C1-C4 decyloxy group, a C2-C4 fluorene carbonyl group, C2-C4 anthraceneoxycarbonyl and C6-C8 aryl;
- the ruthenium and osmium are each independently hydrogen or a substituted or unsubstituted C1-C6 fluorenyl group, and A and B are not simultaneously hydrogen, wherein the substituted substituent is selected from the group consisting of halogen, cyano, nitro, hydroxy and amino groups. ;
- a and B together with the attached carbon atom form a substituted or unsubstituted C4-C7 aliphatic ring or a substituted or unsubstituted C6-C8 aromatic ring, wherein the substituted substituent is selected from the group consisting of halogen and cyano. , nitro, hydroxy and amino groups;
- X is hydrogen, halogen, hydroxy or cyano
- Y is hydrogen or a substituted or unsubstituted C1-C6 alkyl group, and the substituted substituent is selected from the group consisting of 3 ⁇ 4, cyano, nitro, hydroxy, amino, C1-C4 decyloxy, C2-C4 fluorene carbonyl, C2 -C4 oxime carbonyl, C2-C4 alkenyl, C2-C4 alkynyl and C6-C8 aryl;
- G is hydrogen, C1-C4 fluorenyl, C1-C4 decyloxy, C2-C4 fluorenylcarbonyl, C1-C4 decylamino or (C1-C4 fluorenyl) 2 amino;
- Z is hydrogen, C1-C4 fluorenyl, C1-C4 decyloxy, C2-C4 fluorenylcarbonyl, C1-C4 decylamino or (C1-C4 fluorenyl) 2 amino;
- R is selected from hydrogen or a substituted or unsubstituted C1-C6 fluorenyl group; the substituted substituent is selected from the group consisting of halogen, cyano, nitro, hydroxy and amino;
- ⁇ and ⁇ are each independently hydrogen or a C1-C4 fluorenyl group, and A and B are not hydrogen at the same time;
- a and B together with the attached carbon atom form a substituted or unsubstituted C4-C6 aliphatic ring or substitution or An unsubstituted C6-C8 aromatic ring, wherein the substituted substituent is selected from the group consisting of halogen, cyano, nitro, hydroxy and amino;
- X is hydrogen, halogen, hydroxy or cyano;
- Y is hydrogen or a substituted or unsubstituted C1-C4 alkyl group, and the substituted substituent is selected from the group consisting of a tetra-, a cyano group, a nitro group, a hydroxyl group, an amino group, a C1-C4 alkoxy group, a C2-C4 anthraceneoxycarbonyl group, C2-C4 alkenyl and phenyl;
- G is hydrogen, C1-C4 fluorenyl, C1-C4 decyloxy, C1-C4 decylamino or (C1-C4 fluorenyl) 2 amino
- Z is hydrogen, C1-C4 fluorenyl, C1-C4 decyloxy , C1-C4 mercaptoamino or (C1-C4 fluorenyl) 2 amino
- Y, G and hydrazine are not hydrogen at the same time;
- R is selected from hydrogen or a substituted or unsubstituted C1-C4 fluorenyl group; the substituted substituent is selected from the group consisting of halogen, cyano, nitro, hydroxy and amino;
- ⁇ and ⁇ are each independently hydrogen or methyl, and A and B are not hydrogen at the same time;
- a and B together with the attached carbon atoms form a benzene ring
- X is hydrogen or halogen
- Y is hydrogen, methyl, 2,2,2-trifluoroethyl, allyl, ethoxycarbonylethyl or benzyl;
- G is hydrogen, methyl, ethyl, methoxy or dimethylamino
- Z is hydrogen, methyl, ethyl, methoxy or dimethylamino
- R is hydrogen, monofluoromethyl, difluoromethyl or trifluoromethyl.
- piperazin triazole compounds of Formula I may also exist in the form of tautomers.
- the tautomeric form of the piperazin triazole compound represented by the general formula I may include, but is not limited to, a structure represented by the following formula II:
- Typical compounds of the invention include, but are not limited to, the following compounds: L
- Another aspect of the present invention provides a process for the preparation of a piperazin triazole compound represented by Formula I, which comprises the following steps:
- HBTU is benzotriazole-oxime, oxime, ⁇ ', ⁇ '-tetramethylurea Fluorophosphate
- DIPEA is diisopropylethylamine
- DMF is hydrazine, hydrazine-dimethylformamide.
- the raw material S (leq) and the purchased or synthesized amine D (leq) were dissolved in DMF, and HBTU and DIPEA were sequentially added in an ice bath, and the temperature was gradually raised to room temperature overnight. Water was added to the ice bath, extracted with methylene chloride, and the dichloromethane layer was washed with saturated brine, dried, evaporated, and then purified by column chromatography to obtain the piperazine and triazole compound of the formula I.
- Still another aspect of the present invention provides the use of a piperazine triazole compound represented by Formula I or an isomer thereof or a pharmaceutically acceptable salt, ester, prodrug or hydrate thereof as a novel high Use of a selective PARP1 inhibitor for the preparation of a medicament for the prevention and/or treatment of a disease associated with PARP (poly ADP-ribose polymerase), ie various ischemic diseases (brain, umbilical cord, heart, Digestive tract, retina, etc.), neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, muscular dystrophy, etc.) and cancer (breast cancer, ovarian cancer, liver cancer, melanoma, prostate cancer, colon cancer, stomach cancer) And other solid tumors, etc.).
- PARP poly ADP-ribose polymerase
- ie various ischemic diseases brain, umbilical cord, heart, Digestive tract, retina, etc.
- neurodegenerative diseases Parkinson's disease, Alzheimer's disease
- a pharmaceutical composition comprising a therapeutically effective amount of one or more piperazine-triazole compounds represented by Formula I, or a pharmaceutically acceptable salt, ester thereof, Prodrugs and or hydrates thereof, and may optionally further comprise a pharmaceutically acceptable carrier or excipient.
- a PARP1 inhibitor comprising a therapeutically effective amount of one or more piperazine-triazole compounds represented by Formula I, or a pharmaceutically acceptable salt, ester thereof, Prodrugs and or hydrates thereof, and may optionally further comprise a pharmaceutically acceptable carrier or excipient.
- a further aspect of the invention provides a method of preventing and/or treating a disease associated with PARP, the method comprising administering a therapeutically effective amount of a piperazine-triazole compound represented by Formula I, or a pharmaceutically acceptable salt thereof, The ester, prodrug and or hydrate thereof or the above pharmaceutical composition of the present invention are administered to a patient.
- DRAWINGS Figure 1 is a spectrum of the racemate S3;
- Figure 2 is an optical isomer S3-(+) spectrum
- Figure 3 shows the optical isomer S3-(-) spectrum.
- ⁇ - MR was measured with a Varian Mercury AMX300 model; MS was measured with a VG ZAB-HS or VG-7070 meter, except for the EI source (70 ev); all solvents were re-distilled before use, none used
- the water solvent is obtained by drying according to the standard method; except for the description, all the reactions are carried out under the protection of nitrogen and traced by TLC.
- silica gel (200 300 mesh) column chromatography was used except for the description; silica gel (200 300 mesh) was produced by Qingdao Ocean Chemical Plant, and GF254 thin layer silica gel plate was produced by Yantai Jiangyou Silica Development Co., Ltd.
- HBTU is benzotriazole- ⁇ , ⁇ , ⁇ ', ⁇ '-tetramethylurea hexafluorophosphate
- DIPEA is diisopropylethylamine
- DMF is N,N-dimethylformamide.
- the S2 synthesis method is the same as SI.
- Analytical data for S2 ⁇ NMR POO MHz, CDC1 3 ) ⁇ 11.59 (s, 0.65 ⁇ ), 11.47 (s, 0.35H), 8.56 ⁇ 8.29 (m, 1H), 7.90 ⁇ 7.59 (m, 3H), 7.33 ( m, 2H), 7.06 (m, 1H), 6.21 ⁇ 6.17 (m, 0.5H), 5.86 (m, 0.5H), 5.47 ⁇ 4.72 (m, 3H), 4.30 (s, 2H), 4.21 -3.82 ( m, 2H), 3.71 (m, 1H), 3.47 - 2.47 (m, 3H).
- the S3 synthesis method is the same as SI.
- the S4 synthesis method is the same as SI.
- the synthetic reference for the starting material 5-1 is J Met/. Chem. 2008, 57, 5 ⁇ -602.
- the synthetic reference for the raw material 6-1 is J Met/. Chem. 2008, 57, 559-602 0
- the S6 synthesis method is the same as SI.
- the synthesis reference of the raw material 7-1 is J Met/. Chem. 2008, 51, 589-602, and TMEDA is tetramethylethylenediamine.
- the raw material 7-1 (1 eq) was dissolved in tetrahydrofuran, TMEDA (1.5 eq) was added at -78 °C, n-BuLi was slowly added dropwise after 0 min, and allyl bromide was added after 0 min, and closed 20 min after the completion of the dropwise addition. Refrigeration. After the saturated ammonium chloride was quenched, it was extracted twice with dichloromethane, and the dichloromethane layer was washed with saturated brine, dried, evaporated and evaporated.
- the raw material 7-2 was dissolved in ethanol, and 6N hydrochloric acid was added thereto, and the mixture was stirred at room temperature overnight, and the solvent was evaporated to dryness.
- the S7 synthesis method is the same as S1.
- the S8 synthesis method is the same as S1.
- Analytical data for the compound S8 iH NMR (300 MHz, CDC1 3 ) ⁇ 11.70, 0.5 ⁇ ), 11.46 (s, 0.5H), 8.44 (s,lH), 7.78 (m, 3H), 7.43 ⁇ 6.68 (m, 7H), 6.35 (s,lH), 5.28 (m,H), 5.17 ⁇ 4.67 (m,lH), 4.30 (s, 2H), 4.09 (m,2H), 3.48 ⁇ 3.14 (m, 2H), 1.75 -1.48 (m, 3H).
- the raw material 10-1 was dissolved in 80% hydrazine hydrate, heated to 120 ° C for reaction, and after completion of the reaction, it was cooled to room temperature, and then placed in a refrigerator. A large amount of solid was precipitated, filtered, and dried to obtain a crude product 10-2.
- iH NMR 300 MHz, DMSO
- the intermediate 12-1 is a reference to the Journal of Natural Products, 2011, 74(7), 1630-1635.
- the synthesis of the intermediate 12-4 is carried out in the same manner as in the 11-4 synthesis, and the intermediate 12-7 is obtained by the synthesis of the intermediate 7-3 described above, and finally condensed to give the final product S12.
- the intermediate 17-3 was dissolved in methanol, and an appropriate amount of palladium carbon was added thereto, and the mixture was replaced with hydrogen, and the mixture was stirred at room temperature overnight. After the reaction was completed, palladium carbon was filtered off and concentrated to give crude crude product.
- the synthesis of the fragment 19-1 is the same as the synthesis method of the fragment 5-1.
- the S20 synthesis method is the same as SI.
- the S21 synthesis method is the same as SI.
- the full-length plasmid of PARP1 was amplified by PCR, digested, ligated and transformed into DH5a to obtain HTb-PARP1 positive clones. After extraction and restriction enzyme digestion, PCR was carried out to identify D-Bobac, and Bacmid/PARP was identified by PCR. The virus was collected, the cells were lysed, and the PARP1 protein was purified by affinity chromatography and identified by Western blotting.
- the substrate histone, NAD + and DNA and the expressed PARP1 enzyme are coated, placed in a 96-well plate reaction system, optimized and finally determined various reaction conditions, and the reaction product PAR is reacted with PAR mAb, and after adding the secondary antibody, The OD value was read with a microplate reader, and the degree of inhibition of PARP1 enzyme activity was calculated based on this, as shown in Table 1.
- Negative value indicating no growth and inhibition of growth, can be regarded as 0;
- the new compound not only has high activity at the PARP 1 enzyme level, but also exhibits significant activity on the PARP1 directly related cell VC8, and some compounds are 12 times more active than the positive compound AZD2281.
- the tumor tissue in the vigorous growth period was cut into 1.5 mm 3 and inoculated subcutaneously in the right axilla of the nude mice under aseptic conditions.
- the nude mice were subcutaneously transplanted with a vernier caliper to measure the diameter of the transplanted tumor. After the tumor was grown to 100-200 mm 3 , the animals were randomly divided into groups. S3 was 100 mg/kg and 25 mg/kg, and the positive drug AZD2281 was 100 mg/kg. All were administered orally once a day for three weeks; in the solvent control group, the same amount of normal saline was given.
- the diameter of the transplanted tumor was measured twice a week during the entire experiment, and the body weight of the mice was weighed.
- Compound S3 does have significant antitumor activity in vivo, and the inhibition of tumor at 25 mg/kg is comparable to that of the positive compound at 100 mg/kg. At 100 mg/kg, the tumor completely disappears. . More importantly, Compound S3 showed no significant side effects at both doses.
- such a piperazine-triazole compound having one or more substituents represented by the compound S3 has an extremely high PARP1 enzyme inhibitory activity, and the cell activity is also significantly higher than that of the positive compound AZD2281.
- the presence of the substituents on the ring also significantly increased the selectivity of the compounds for telomerase TNKS1 and TNKS2, and the risk of cardiotoxicity was small.
- the tumor inhibition was also significantly higher in the PARP1 mouse model than in the positive compounds. Therefore, these compounds are useful as novel high-selective ribose poly ADP-ribose polymerase-1 (PARP1) inhibitors for the prevention and/or treatment of PARP-related diseases.
- PARP1 novel high-selective ribose poly ADP-ribose polymerase-1
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2880739A CA2880739C (en) | 2012-08-01 | 2013-07-24 | Piperazinotriazole compound, preparation method thereof, and use thereof in drug preparation |
EP13825341.4A EP2881395B1 (en) | 2012-08-01 | 2013-07-24 | Piperazinotriazole compound, preparation method therefor, and use thereof in drug preparation |
AU2013299117A AU2013299117B2 (en) | 2012-08-01 | 2013-07-24 | Piperazinotrizole compound, preparation method therefor, and use thereof in drug preparation |
JP2015524614A JP6043935B2 (ja) | 2012-08-01 | 2013-07-24 | ピペラジノトリアゾール化合物及びその製造方法と製薬用途 |
US14/418,705 US9255106B2 (en) | 2012-08-01 | 2013-07-24 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as PARP-1 inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210272101.5 | 2012-08-01 | ||
CN201210272101.5A CN103570725B (zh) | 2012-08-01 | 2012-08-01 | 哌嗪并三唑类化合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014019468A1 true WO2014019468A1 (zh) | 2014-02-06 |
Family
ID=50027238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/079998 WO2014019468A1 (zh) | 2012-08-01 | 2013-07-24 | 哌嗪并三唑类化合物及其制备方法和制药用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9255106B2 (zh) |
EP (1) | EP2881395B1 (zh) |
JP (1) | JP6043935B2 (zh) |
CN (1) | CN103570725B (zh) |
AU (1) | AU2013299117B2 (zh) |
CA (1) | CA2880739C (zh) |
WO (1) | WO2014019468A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017101796A1 (zh) * | 2015-12-16 | 2017-06-22 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
US9856262B2 (en) | 2014-04-10 | 2018-01-02 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors |
JP2018516979A (ja) * | 2015-05-18 | 2018-06-28 | 中国科学院上海薬物研究所 | Somcl−9112固体分散体、その製造方法およびそれを含むsomcl−9112固体製剤 |
EP3381919A4 (en) * | 2015-11-23 | 2018-11-21 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof |
US10800784B2 (en) | 2018-02-01 | 2020-10-13 | Japan Tobacco Inc. | Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
US20160193210A1 (en) | 2013-07-18 | 2016-07-07 | Taiho Pharmaceutical Co., Ltd. | Antitumor drug for intermittent administration of fgfr inhibitor |
TW201536293A (zh) | 2013-07-18 | 2015-10-01 | Taiho Pharmaceutical Co Ltd | 對fgfr抑制劑具耐受性之癌的治療藥 |
CN107406455B (zh) | 2015-03-31 | 2020-05-12 | 大鹏药品工业株式会社 | 3,5-二取代的苯炔基化合物晶体 |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
EP4353222A1 (en) | 2018-03-19 | 2024-04-17 | Taiho Pharmaceutical Co., Ltd. | Use of sodium alkyl sulfate |
PE20211382A1 (es) * | 2018-04-30 | 2021-07-27 | Ribon Therapeutics Inc | Piridazinonas como inhibidoras de parp7 |
US11691969B2 (en) | 2019-10-30 | 2023-07-04 | Ribon Therapeutics, Inc. | Pyridazinones as PARP7 inhibtors |
KR20230167755A (ko) * | 2021-02-09 | 2023-12-11 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Parp7 억제제로서 유용한 트리시클릭 유도체 |
WO2022242750A1 (zh) * | 2021-05-21 | 2022-11-24 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
CN115477640A (zh) * | 2021-05-31 | 2022-12-16 | 由理生物医药(上海)有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
WO2023288002A1 (en) * | 2021-07-16 | 2023-01-19 | Oregon Health & Science University | Phthalazinone-based parp-1 inhibitors |
WO2023001247A1 (zh) * | 2021-07-21 | 2023-01-26 | 南京明德新药研发有限公司 | 哒嗪酮类化合物 |
WO2023006013A1 (zh) * | 2021-07-29 | 2023-02-02 | 上海齐鲁制药研究中心有限公司 | 新型parp7抑制剂及其应用 |
TW202346294A (zh) * | 2022-04-21 | 2023-12-01 | 大陸商四川海思科製藥有限公司 | 吡嗪酮衍生物及其在醫藥上的應用 |
WO2024037558A1 (en) * | 2022-08-17 | 2024-02-22 | Jacobio Pharmaceuticals Co., Ltd. | Solid forms of compound i or salts thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007138351A2 (en) | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
US20080161280A1 (en) | 2006-12-28 | 2008-07-03 | Abbott Laboratories | Inhibitors of poly(adp-ribose)polymerase |
CN101855221A (zh) * | 2007-11-15 | 2010-10-06 | P.安杰莱蒂分子生物学研究所 | 作为parp抑制剂的哒嗪酮衍生物 |
WO2012019427A1 (zh) * | 2010-08-09 | 2012-02-16 | 上海恒瑞医药有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
WO2012072033A1 (zh) * | 2010-12-03 | 2012-06-07 | 苏州科瑞戈医药科技有限公司 | 取代的2,3-二氮杂萘酮化合物及其用途 |
CN102898377A (zh) * | 2012-02-14 | 2013-01-30 | 南京圣和药业有限公司 | 一类新型酞嗪酮衍生物及其用途 |
CN103172619A (zh) * | 2011-12-20 | 2013-06-26 | 齐鲁制药有限公司 | 4-(取代苄基)-1(2h)-2,3-二氮杂萘酮类衍生物及其制备方法、药物组合物和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
-
2012
- 2012-08-01 CN CN201210272101.5A patent/CN103570725B/zh active Active
-
2013
- 2013-07-24 US US14/418,705 patent/US9255106B2/en active Active
- 2013-07-24 JP JP2015524614A patent/JP6043935B2/ja active Active
- 2013-07-24 EP EP13825341.4A patent/EP2881395B1/en active Active
- 2013-07-24 CA CA2880739A patent/CA2880739C/en active Active
- 2013-07-24 WO PCT/CN2013/079998 patent/WO2014019468A1/zh active Application Filing
- 2013-07-24 AU AU2013299117A patent/AU2013299117B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007138351A2 (en) | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
US20090176765A1 (en) * | 2006-05-31 | 2009-07-09 | Philip Jones | Pyridinone and Pyridazinone Derivatives as Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) |
US20080161280A1 (en) | 2006-12-28 | 2008-07-03 | Abbott Laboratories | Inhibitors of poly(adp-ribose)polymerase |
CN101641014A (zh) * | 2006-12-28 | 2010-02-03 | 艾博特公司 | 聚(adp-核糖)聚合酶抑制剂 |
CN101855221A (zh) * | 2007-11-15 | 2010-10-06 | P.安杰莱蒂分子生物学研究所 | 作为parp抑制剂的哒嗪酮衍生物 |
WO2012019427A1 (zh) * | 2010-08-09 | 2012-02-16 | 上海恒瑞医药有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
WO2012072033A1 (zh) * | 2010-12-03 | 2012-06-07 | 苏州科瑞戈医药科技有限公司 | 取代的2,3-二氮杂萘酮化合物及其用途 |
CN103172619A (zh) * | 2011-12-20 | 2013-06-26 | 齐鲁制药有限公司 | 4-(取代苄基)-1(2h)-2,3-二氮杂萘酮类衍生物及其制备方法、药物组合物和用途 |
CN102898377A (zh) * | 2012-02-14 | 2013-01-30 | 南京圣和药业有限公司 | 一类新型酞嗪酮衍生物及其用途 |
Non-Patent Citations (7)
Title |
---|
FATIMA, S. ET AL.: "Molecular docking and 3D-QSAR studies on inhibitors of DNA damage signaling enzyme human PARP-1", JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION 1079-9893, vol. 32, no. 4, 1 August 2012 (2012-08-01), pages 214 - 224, XP008176567 * |
J MED. CHEM., vol. 51, 2008, pages 589 - 602 |
J. MED. CHEM., vol. 51, 2008, pages 589 - 602 |
J. MED. CHEM., vol. 51, 2008, pages 6581 - 6591 |
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 42, no. 4, 2005, pages 691 - 694 |
JOURNAL OF NATURAL PRODUCTS, vol. 74, no. 7, 2011, pages 1630 - 1635 |
See also references of EP2881395A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9856262B2 (en) | 2014-04-10 | 2018-01-02 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors |
JP2018516979A (ja) * | 2015-05-18 | 2018-06-28 | 中国科学院上海薬物研究所 | Somcl−9112固体分散体、その製造方法およびそれを含むsomcl−9112固体製剤 |
US11191761B2 (en) | 2015-05-18 | 2021-12-07 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | SOMCL-9112 solid dispersion and preparation method thereof and SOMCL-9112 solid preparation containing SOMCL-9112 solid dispersion |
EP3381919A4 (en) * | 2015-11-23 | 2018-11-21 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof |
US10597399B2 (en) | 2015-11-23 | 2020-03-24 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted triazolopiperazine PARP inhibitor, preparation method therefor and use thereof |
WO2017101796A1 (zh) * | 2015-12-16 | 2017-06-22 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
CN107207504A (zh) * | 2015-12-16 | 2017-09-26 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
US10800784B2 (en) | 2018-02-01 | 2020-10-13 | Japan Tobacco Inc. | Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof |
Also Published As
Publication number | Publication date |
---|---|
US20150166544A1 (en) | 2015-06-18 |
CN103570725B (zh) | 2017-03-22 |
US9255106B2 (en) | 2016-02-09 |
CA2880739A1 (en) | 2014-02-06 |
JP2015527336A (ja) | 2015-09-17 |
AU2013299117B2 (en) | 2016-02-18 |
EP2881395A4 (en) | 2016-02-24 |
JP6043935B2 (ja) | 2016-12-14 |
EP2881395B1 (en) | 2018-09-05 |
EP2881395A1 (en) | 2015-06-10 |
CA2880739C (en) | 2017-05-30 |
AU2013299117A1 (en) | 2015-03-19 |
CN103570725A (zh) | 2014-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014019468A1 (zh) | 哌嗪并三唑类化合物及其制备方法和制药用途 | |
US9273052B2 (en) | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | |
US20210238184A1 (en) | Therapeutic compounds | |
WO2021190467A1 (zh) | 含螺环的喹唑啉化合物 | |
CA3213029A1 (en) | Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof | |
TW200901992A (en) | Triazolopyridine carboxamide and triazolopyrimidine carboxamide derivatives, their preparation and their application in therapeutics | |
WO2018133795A1 (zh) | 一种ezh2抑制剂及其用途 | |
US11267815B2 (en) | Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof | |
JP2015038112A (ja) | フェノキシメチル複素環化合物 | |
TW201840564A (zh) | 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途 | |
CN116323625A (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
WO2017088723A1 (zh) | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 | |
CN108368059A (zh) | 一种取代的酞嗪酮化合物及其药物组合物 | |
JP5822080B2 (ja) | キノキサリン化合物 | |
JP2021505132A (ja) | 核酸結合光プローブおよびその使用 | |
CN116514846A (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
WO2022171088A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物 | |
WO2020118753A1 (zh) | 一种喹啉结构的pan-KIT激酶抑制剂及其用途 | |
TWI548637B (zh) | 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用 | |
WO2021071982A1 (en) | Compounds for modulating splicing | |
CN116162099A (zh) | 杂环类衍生物及其制备方法和用途 | |
CN116157400A (zh) | 杂环类衍生物及其制备方法和用途 | |
CN116332938A (zh) | 稠合三环类衍生物及其制备方法和用途 | |
NZ765772B2 (en) | Pharmaceutical composition for the treatment of cancer | |
BR112018006498B1 (pt) | Composto, uso do mesmo e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13825341 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14418705 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2880739 Country of ref document: CA Ref document number: 2015524614 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013825341 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013299117 Country of ref document: AU Date of ref document: 20130724 Kind code of ref document: A |